Clinical Trial Update: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the IDH2 inhibitor AG-221 (enasidenib) in IDH2-mutated myelodysplastic syndrome; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Enasidenib (Idhifa) (enasidenib)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes, Leukemia Acute Myeloid | Phase 2 | Status: ACTIVE_NOT_RECRUITING